Simvastatin goes off patent in late June; Ranbaxy gets 180-day exclusivity period; Dr Reddy's-Merck will be third player.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
Domestic firms Aurobindo Pharma, Glenmark Pharmaceuticals and Natco Pharma have received US health regulator's approval to market their generic Rizatriptan Benzoate orally disintegrating tablets used for treating migraine in the American market.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
It takes 6 to 8 months after the approval for a product to hit stores.
A large number of American companies like Google, Uber and IBM are offering their resources to help India successfully fight the battle against the deadly coronavirus pandemic.
US-based global technology giant IBM expressed keen interest in participating in India's newly-launched initiatives like Smart Cities and Digital India.
Roche has already adapted its business model in India to increase affordable access to drugs and try to stave off trouble from India's patent authorities.
Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.
The deal would involve Pfizer paying with 11.3 of its shares for each Allergan share.
Defence major Boeing on Monday proposed greater business engagement with India, as Prime Minister Narendra Modi promised the US companies to provide friendlier business environment in the country.
Sun Pharma open to large acquisitions post Ranbaxy.
Ties between India and the United States have been strained in recent years because of trade policies and patent disputes.
Rediff.com brings you these and other exciting news from the week gone by in this photo feature...
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Food regulator has closed more than 15 files.
He is meeting stalwarts such as Google's Eric E Schmidt, Carlyle's David M Rubenstein, Cargill's David W MacLennan, MasterCard's Ajay Banga, and Pepsico's Indra Nooyi.
Indian American Harvard Medical School student Sachin Jain looks beyond boundaries of direct service.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
Most successful and ambitious business leaders feel persuaded that they have no competent successor, says R G Vilakudi.
Unlike India, the US is a free-pricing market.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
It could also ease the burden on the 225 million women in developing countries, says Ari Altstedter.
.jpg)
According to information available on the European Commission website, Ranbaxy Laboratories has been fined euro 10.32 million (over Rs 80 crore).
'Younger people are taking steps to prevent lifestyle diseases.'
'It is fascinating to partner with consumers on the journey of self-discovery and to help shape people's preferences -- that is what I find most exciting,' Nandini Piramal tells Abhineet Kumar and Aneesh Phadnis.
As Prime Minister Narendra Modi arrived in New York on Friday on a five-day US visit, he was greeted with 'Har Har Modi' slogan.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances